Építés alatt – nem éles oldal
Belépés
Toborzás még nem indultFázis nélkül

The Potential of Mesenchymal Stromal Stem Cells to Correct Immune and Metabolic Dysfunctions in Circulating Immune Cells During Sepsis: An Ex Vivo Pilot Study.

A legfontosabb adatok

Ki végzi
Centre Hospitalier Universitaire Dijon
Hol
Franciaország1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toborzás még nem indult
Résztvevők
51 fő, tervezett
Kezdés
2026. szept.
Várható befejezés
2028. dec.
A vizsgálat típusa
Megfigyeléses
A vizsgált kezelések
  • Blood sample
A regiszteradat frissítve
2026. szeptember 10.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 10 feltétel megnézéseKevesebb

Ki vehet részt

  • Patient or authorized representative, informed and having given consent
  • Age ≥ 18 years
  • Patients admitted for sepsis defined by the association as:; Clinically or microbiologically documented infection; SOFA-2 score ≥ 2; Or +2 points if pre-existing organ dysfunction
  • Complicated; ARDS (Berlin criteria (1)); Acute respiratory failure; AND Bilateral pulmonary opacities (X-ray or CT scan) with no evidence of predominant hydrostatic edema; AND PaO₂/FiO₂ ≤ 300 mmHg under invasive or non-invasive ventilation with PEEP ≥ 5 cmH₂O; or septic shock (2); Vasopressors required to maintain mean arterial pressure (MAP) ≥ 65 mmHg; AND arterial lactate > 2 mmol/L; AND despite adequate fluid resuscitation
  • Blood sample may be collected within 72 hours of admission to the intensive care unit

Ki nem vehet részt

  • Known severe immunodeficiency prior to sepsis:; cytostatic chemotherapy within the previous 3 months,; previously known neutropenia < 500/mm³ (within the past month) not attributed to sepsis,; active hematologic malignancy currently undergoing treatment,; allogeneic bone marrow transplant < 1 year ago,; solid organ transplant receiving immunosuppressants; corticosteroid therapy ≥ 0.5 mg/kg/day of prednisone equivalent for > 3 weeks,; anti-TNF or anti-IL-6 biologic therapy within the past 3 months,; HIV infection with a detectable viral load while not on treatment; Secondary exclusion criteria :
  • Individuals not enrolled in or not eligible for a social security program
  • Individuals subject to a legal protection order
  • Pregnant women, women in labor, or breastfeeding women
  • A diagnosis of sepsis was ruled out following a comprehensive medical evaluation and/or an alternative diagnosis was identified that explains the elevated SOFA-2 score

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Sepsis is a life-threatening organ dysfunction caused by the host's dysregulated immune response to infection. It represents a major global public health challenge. A state of post-septic compensatory immunosuppression may contribute to excess mortality by promoting secondary infections, thereby prolonging the stay in the intensive care unit and increasing the risk of death.

A teljes eredeti leírásKevesebb

New therapeutic strategies to complement antimicrobial treatments-which may correct sepsis-induced functional alterations in immune cells (such as endotoxin tolerance and reduced HLA-DR expression), partly mediated by metabolic abnormalities-are currently being investigated. Among these, mesenchymal stromal cells (MSCs) appear particularly promising. They are capable of reprogramming immune cells by redirecting certain metabolic pathways, notably improving mitochondrial function. MSCs generally have an anti-inflammatory effect in preclinical models of infection, particularly in the early phase of severe ventilated pneumonia, as illustrated by the animal model we have developed, and preliminary trials are currently underway in humans. The ability of CSMs to correct sepsis-induced immunosuppression has not yet been explored. Nevertheless, CSMs possess the ability to communicate with the inflammatory microenvironment in which they are found, conferring plasticity to their response.

We hypothesize that CSMs could correct certain immune and metabolic dysfunctions in circulating immune cells from patients with sepsis meeting severity criteria who are admitted to the intensive care unit.

Furthermore, priming (or prior stimulation) of CSMs could enable a more precise and personalized therapeutic approach, with the possibility of directing CSMs toward a pro-inflammatory (CSM1) or anti-inflammatory (CSM2) phenotype through prior incubation with specific agonists (LPS; IFN-γ/TNF, respectively) before their administration. Depending on the patient's immune status (pro-inflammatory or anti-inflammatory phase), such a personalized approach would optimize treatment with CSMs.

A vizsgálat csoportja

  • Patient with sepsis complicated by ARDS or septic shock

    Kezelés: Blood sample

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2026. szeptember 10.